Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Pavel Vodárek
Five Years of Experience With Rituximab Plus High-Dose Dexamethasone for Relapsed/Refractory Chronic Lymphocytic Leukemia
Archives of Medical Science
Medicine
Related publications
Cost-Utility of Idelalisib in Combination With Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Rituximab in Combination With High-Dose Methylprednisolone for the Treatment of Chronic Lymphocytic Leukemia
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Rituximab–cyclophosphamide–dexamethasone Combination in the Management of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Pomalidomide Plus Low-Dose Dexamethasone Versus High-Dose Dexamethasone Alone for Patients With Relapsed and Refractory Multiple Myeloma (MM-003): A Randomised, Open-Label, Phase 3 Trial
The Lancet Oncology
Oncology
High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902
Leukemia Research
Cancer Research
Oncology
Hematology
The PI3Kδ INHIBITOR ME-401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
